ArticleFrontiers in immunology2026
Theaflavins counteract free fatty acid-driven oxidative-inflammatory injury in endothelial cells through Nrf2-NF-κB axis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronically elevated circulating free fatty acids (FFAs) are key drivers of lipotoxic injury by triggering a self-amplifying oxidative stress-inflammation cascade, thereby contributing to metabolic and cardiovascular diseases. Vascular endothelial dysfunction represents an early and causal event in this process. Although black tea-derived theaflavins (TFs) possess antioxidant and anti-inflammatory properties, the subtype-specific and tissue-parallel effects of TFs against FFA-induced oxidative-inflammatory injury remain incompletely understood. Methods: FFA-induced lipotoxicity models were established in vascular endothelial cells and hepatocytes to systematically compare the protective effects of four major TF subtypes: theaflavin (TF1), theaflavin-3-gallate (TF2A), theaflavin-3'-gallate (TF2B), and theaflavin-3, 3'-digallate (TFDG). Antioxidant capacity was assessed using both cell-free systems and oxidant-stimulated cellular models. Mechanistic studies were conducted to determine the involvement of the Nrf2-NF-κB axis. Results: All TF subtypes significantly attenuated FFA-induced ROS overproduction, lipid peroxidation, and inflammatory mediator release in both endothelial cells and hepatocytes, whereas no major changes in intracellular lipid accumulation were observed. Among the four subtypes, TF1 consistently exhibited the strongest and most reproducible cytoprotective effects. Further analyses demonstrated that TFs, particularly TF1, restored cellular redox homeostasis not only through direct free radical scavenging but, more importantly, through activation of endogenous antioxidant defenses. Transcriptomic and bioinformatics analyses indicated that TF1 enhanced antioxidant-related gene expression while suppressing inflammatory genes, with enrichment of oxidative stress-, atherosclerosis-, and NF-κB-related pathways and Nrf2 appearing as a key node. Molecular docking predicted a favorable TF1-Keap1 interaction. Consistently, TF1 promoted Nrf2 nuclear translocation and HO-1 expression, restored SOD2 and GPX1 expression, reduced mitochondrial ROS, and attenuated IκBα phosphorylation and NF-κB p65 nuclear accumulation. Silencing Nrf2 markedly weakened these protective effects, supporting an important role of Nrf2 in TF1-mediated endothelial protection. Conclusion: TFs act as natural modulators of FFA-driven oxidative-inflammatory injury, with TF1 emerging as the most potent subtype. TF1 protects against FFA-induced endothelial dysfunction partly through an Nrf2-associated mechanism involving enhanced antioxidant responses and attenuation of NF-κB-related inflammatory signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.